Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 10/20 | 0.41 |
| ▸ | CDK2 | P24941 | 10/20 | 0.41 |
| ▸ | CCNE2 | O96020 | 9/20 | 0.41 |
| ▸ | CDK4 | P11802 | 7/20 | 0.37 |
| ▸ | CDK1 | P06493 | 6/20 | 0.37 |
| ▸ | CCND1 | P24385 | 6/20 | 0.37 |
| ▸ | CCNB2 | O95067 | 5/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.37 |
| ▸ | CCNB3 | Q8WWL7 | 5/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.37 |
| ▸ | MYC | P01106 | 2/20 | 0.36 |
| ▸ | MAX | P61244 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1342817 | 0.83 | ADRB2 (0.40) | CCNE1CDK2LPAR1MYCMAX | |
| SCHEMBL1342497 | 0.82 | ITGB1 (0.42) | CCNE1CDK2LPAR1MYCMAX | |
| SCHEMBL1342939 | 0.82 | GAA (0.38) | CCNE1CDK2CCNE2CDK4CDK1 | |
| SCHEMBL1342455 | 0.82 | FFAR2 (0.43) | CCNE1CDK2LPAR1MYCMAX | |
| SCHEMBL1343586 | 0.81 | CCNE1 (0.38) | CCNE1CDK2CCNE2LPAR1MYC | |
| SCHEMBL1341159 | 0.81 | MYC (0.42) | LPAR1MYCMAXMEN1KMT2A | |
| SCHEMBL1343072 | 0.81 | IDH2 (0.47) | LPAR1MYCMAXMEN1KMT2A | |
| SCHEMBL1342982 | 0.81 | FBP1 (0.48) | LPAR1 | |
| SCHEMBL1341150 | 0.80 | PKM (0.41) | LPAR1KMT2A | |
| SCHEMBL1342940 | 0.80 | FFAR1 (0.38) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE45670-E1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| EP-2471533-A1 | Aryl carbonyl derivatives as therapeutic agents | Novo Nordisk A/S (DK) | 2012-07-04 | — | — | EP | disclosed |
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2011-12-08 | — | — | US | disclosed |
| US-8063081-B2 | N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| US-7897628-B2 | {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-03-01 | — | — | US | disclosed |
| US-7541373-B2 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2009-06-02 | — | — | US | disclosed |
| US-7384967-B2 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-06-10 | — | — | US | disclosed |
| US-20080119454-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-20060183783-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2006-08-17 | — | — | US | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | GCK, GCKR, PDK2 | CCNE1 4257/4885CDK2 1019/4885CCNE2 3785/4885 |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | CCNE1 4257/4885CDK2 1019/4885CCNE2 3785/4885 |
| US-20060183783-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, PDK3, PDK4 | CCNE1 4222/4885CDK2 1126/4885CCNE2 3444/4885 |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | CCNE1 4257/4885CDK2 1019/4885CCNE2 3785/4885 |
| US-20080119454-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | CCNE1 4257/4885CDK2 1019/4885CCNE2 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.